- Home
- CLDX vs SPRY Comparison
CLDX vs SPRY Comparison
Compare CLDX & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDX
- SPRY
- Stock Information
- Founded
- CLDX N/A
- SPRY 2015
- Country
- CLDX United States
- SPRY United States
- Employees
- CLDX N/A
- SPRY N/A
- Industry
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- CLDX Health Care
- SPRY Health Care
- Exchange
- CLDX Nasdaq
- SPRY Nasdaq
- Market Cap
- CLDX 1.6B
- SPRY 1.8B
- IPO Year
- CLDX 2008
- SPRY N/A
- Fundamental
- Price
- CLDX $24.50
- SPRY $9.96
- Analyst Decision
- CLDX Strong Buy
- SPRY Strong Buy
- Analyst Count
- CLDX 9
- SPRY 5
- Target Price
- CLDX $46.13
- SPRY $31.00
- AVG Volume (30 Days)
- CLDX 1.6M
- SPRY 3.1M
- Earning Date
- CLDX 11-05-2025
- SPRY 11-12-2025
- Dividend Yield
- CLDX N/A
- SPRY N/A
- EPS Growth
- CLDX N/A
- SPRY N/A
- EPS
- CLDX N/A
- SPRY N/A
- Revenue
- CLDX $5,790,000.00
- SPRY $112,339,000.00
- Revenue This Year
- CLDX N/A
- SPRY N/A
- Revenue Next Year
- CLDX N/A
- SPRY $182.40
- P/E Ratio
- CLDX N/A
- SPRY N/A
- Revenue Growth
- CLDX N/A
- SPRY 22367.80
- 52 Week Low
- CLDX $14.40
- SPRY $9.78
- 52 Week High
- CLDX $47.00
- SPRY $18.90
- Technical
- Relative Strength Index (RSI)
- CLDX 57.57
- SPRY 25.38
- Support Level
- CLDX $22.44
- SPRY $9.97
- Resistance Level
- CLDX $25.51
- SPRY $10.78
- Average True Range (ATR)
- CLDX 1.22
- SPRY 0.65
- MACD
- CLDX 0.20
- SPRY -0.07
- Stochastic Oscillator
- CLDX 75.78
- SPRY 4.27
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.